Market Spotlight: Celiac Disease
|出版日期||內容資訊||英文 26 Pages
|麩質過敏症:市場焦點 Market Spotlight: Celiac Disease|
|出版日期: 2020年12月03日||內容資訊: 英文 26 Pages||
This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, recent events and analyst opinion, clinical trials, upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.
Datamonitor Healthcare estimates that in 2019, there were approximately 121.1 million seropositive prevalent cases of celiac disease and 48.0 million prevalent cases of biopsy-proven celiac disease worldwide.
Pooled seroprevalence is estimated to be 1.4%, and the pooled prevalence of biopsy-proven disease is estimated to be 0.7% worldwide.
Half of the industry-sponsored drugs in active clinical development for celiac disease are in Phase II, with only one drug in Phase III.
Therapies in development for celiac disease focus on targets such as zonulin and zonulin receptor, interleukin-15/interleukin-15 receptor, and gluten. Pipeline drugs for celiac disease are administered via the oral and intravenous routes.
The release of topline Phase III trial results for INN-202 is the only high-impact upcoming event in the celiac disease space. The overall likelihood of approval of a Phase I autoimmune/immunology asset is 12.3%, and the average probability a drug advances from Phase III is 66.9%. Drugs, on average, take 9.2 years from Phase I to approval in the overall autoimmune/immunology space.
All clinical trials for celiac disease have been in either Phase I or Phase II.
The US has the highest number of celiac disease clinical trials globally. Clinical trial activity in the celiac disease space is dominated by completed trials. 9 Meters Biopharma has the highest number of completed clinical trials for celiac disease, with six trials.
9 Meters Biopharma leads industry sponsors with the highest overall number of clinical trials for celiac disease.